selected publications
-
Journal Article
- Average clinician-measured blood pressures and cardiovascular outcomes in patients with type 2 diabetes mellitus and ischemic heart disease in the EXAMINE Trial. Journal of the American Heart Association. 2018
- High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. Diabetes, Obesity & Metabolism. 2018
- Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. Clinical Cardiology. 2018
- Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: the EXAMINE trial. Diabetes, Obesity & Metabolism. 2017
- Angiotensin-converting enzyme inhibitor use and major cardiovascular outcomes in type 2 diabetes mellitus treated with the dipeptidyl peptidase 4 inhibitor alogliptin. Hypertension (Dallas, Tex.. 2016
- Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE Trial. Diabetes care. 2016
- Alogliptin after acute coronary syndrome in patients with type 2 diabetes. New England Journal of Medicine. 2013
- EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. American Heart Journal. 2011
-
Abstract